A Novel Transdermal Treatment of Chronic Ocular Graft-Vs-Host Disease (oGvHD): A Phase II Clinic Trial

Chronic GvHD affects about 30-60% of patients after allogeneic hematopoietic cell transplant (allo-HCT), and a majority exhibit ocular manifestations with significant impact on quality of life. In severe cases, oGvHD can lead to permanent vision loss. There is no FDA-approved treatment to date as the current options are limited and mostly ineffective. Forehead application of 1% progesterone gel (Pro-ocular^TM) increases resistance to...